NewAmsterdam Pharma Company NV (NASDAQ:NAMS) currently has a daily average trading volume of 967.44K but it saw 1306329 shares traded in last market. With a market cap of 2.18B USD, the company’s current market price of $19.39 came rising about 3.75 while comparing to the previous closing price of $18.69. In past 52 weeks, the stock remained buoying in the range of price level as high as $27.29 and as low as $14.06.
The company’s shares got several price updates from the analyst firms in past one month and most recent of them is from the Cantor Fitzgerald which initiated the stock as “Overweight” in its note to investors issued on June 04, 2025, recommending a price target of $42 for it.
Over the week, NAMS’s stock price is moving 12.02% up while it is -4.20% when we observe its performance for the past one month. Year-to-date it is -24.55% down and over the past year, the stock is showing an upside performance of 3.41%.
The company is expected to be releasing its next quarterly report in July, for which analysts forecasted an EPS of -0.43 while estimate for next year EPS is -1.6. In next quarter, company is expected to be making quarterly sales of $4.2M as analysts are expecting the sales for current fiscal year at $16.32M and seeing the company making $13.37M in sales next year. Moreover, analysts are in estimates of $1.56M for current-quarter revenue.
Currently, NewAmsterdam Pharma Company NV’s total number of outstanding shares is 112.17M with 0.34% of that held by the insiders while 112.93% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -24.10% and return on equity (ROE) at -31.51%. Stock’s beta reads -0.02. Stock has a price to book (P/B) ratio of 2.80 while price to sale or P/S ratio amounts to 46.18. Its return on asset (ROA) is -28.67% on average.
